retatrutide type 2 diabetes trial Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide produces up to 30.3%
Pay in 4 interest-free payments of $5.65 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2





















:max_bytes(150000):strip_icc()/GettyImages-1331502792-cdc8ea8d1bb3486d96111406aff3ae34.jpg)





